Investing.com - Cidara Therapeutics Inc (NASDAQ: CDTX) reported first quarter EPS of $-0.040, $0.06 better than the analyst estimate of $-0.103. Revenue for the quarter came in at $17.58M versus the consensus estimate of $11.53M.
Cidara Therapeutics Inc's stock price closed at $0.51. It is down -23.870% in the last 3 months and down -54.510% in the last 12 months.
Cidara Therapeutics Inc saw 2 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Cidara Therapeutics Inc's stock price’s past reactions to earnings here.
According to InvestingPro, Cidara Therapeutics Inc's Financial Health score is "fair performance".
Check out Cidara Therapeutics Inc's recent earnings performance, and Cidara Therapeutics Inc's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar